No results for ‘’
Jagsonpal Pharmaceuticals Ltd
₹212.28
(0.82%)
Mon, 22 Jun 2026, 05:24 pm
Health Technology
Pharmaceuticals: Generic
24.5KJagsonpal Pharmaceuticals Enterprise Value (EV)
| Particulars | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price to earnings ratio | 30.30 | 15.79 | 13.33 | 3.29 | 5.51 | 5.72 | 4.49 | 14.44 | 12.64 | 63.33 | 26.41 | 8.41 | 0 | 9.55 | 5.81 | 12.22 | 43.57 | 28.42 | 33.04 | 26.26 |
| Price to book ratio | 1.13 | 0.61 | 0.54 | 0.25 | 0.58 | 0.44 | 0.34 | 0.27 | 0.27 | 0.78 | 0.87 | 0.91 | 0.72 | 0.66 | 0.41 | 1.71 | 6.19 | 4.78 | 3.95 | 5.98 |
| Price to sales ratio | 0.51 | 0.34 | 0.27 | 0.15 | 0.37 | 0.25 | 0.19 | 0.16 | 0.19 | 0.54 | 0.60 | 0.69 | 0.56 | 0.41 | 0.29 | 1.11 | 3.78 | 3.21 | 3.56 | 5.41 |
| Price to cash flow ratio | 50.05 | 18.70 | 2.97 | 0.99 | 59.58 | 6.35 | 12.30 | 3.86 | 12.56 | 0 | 22.93 | 0 | 0 | 2.29 | 3.38 | 6.93 | 100.50 | 15.21 | 17.46 | 23.06 |
| Enterprise value | 118Cr | 90.11Cr | 74.96Cr | 41.22Cr | 65.6Cr | 62.29Cr | 58.52Cr | 49.55Cr | 50.18Cr | 99.25Cr | 109Cr | 87.68Cr | 64.26Cr | 34.15Cr | 12.31Cr | 153Cr | 775Cr | 651Cr | 603Cr | 1335Cr |
| Enterprise value to EBITDA ratio | 8.70 | 8.29 | 5.95 | 2.73 | 4.17 | 4.29 | 3.52 | 4.92 | 4.70 | 11.37 | 9.21 | 14.35 | 0 | 3.66 | 1.43 | 8.01 | 29.63 | 18.40 | 25.46 | 25.82 |
| Debt to equity ratio | 0.60 | 0.68 | 0.54 | 0.35 | 0.23 | 0.31 | 0.35 | 0.34 | 0.36 | 0.41 | 0.39 | 0.07 | 0.08 | 0.04 | 0.06 | 0.06 | 0 | 0.04 | 0.05 | 0.04 |
| Return on equity % | 0 | 3.93 | 4.17 | 7.95 | 11.02 | 7.96 | 7.79 | 1.86 | 2.15 | 1.21 | 3.36 | 11.39 | -11.11 | 7.13 | 7.30 | 14.64 | 14.81 | 18.44 | 12.97 | 25.91 |
Jagsonpal Pharmaceuticals Ltd Enterprise Value
The Jagsonpal Pharmaceuticals Ltd Enterprise Value is a key financial metric used by investors to evaluate Jagsonpal Pharmaceuticals Ltd's valuation, profitability, and overall financial performance. Tracking the Jagsonpal Pharmaceuticals Ltd Enterprise Value helps investors understand whether the stock is undervalued, fairly valued, or trading at a premium compared to its historical performance and industry peers.
Jagsonpal Pharmaceuticals Ltd (NSE: JAGSNPHARM, BSE: 507789) is currently trading at ₹212.28, with a market capitalization of ₹1425.7Cr. As a leading company in the Health technology sector and Pharmaceuticals: generic industry, monitoring the Jagsonpal Pharmaceuticals Ltd Enterprise Value is essential for fundamental analysis.
Jagsonpal Pharmaceuticals Ltd Enterprise Value Current Value
The current Jagsonpal Pharmaceuticals Ltd Enterprise Value stands at 1335Cr.
The latest Jagsonpal Pharmaceuticals Ltd Enterprise Value has increased compared to the previous period, indicating rising valuation or improved investor sentiment.
Jagsonpal Pharmaceuticals Ltd Enterprise Value Historical Trend
The Jagsonpal Pharmaceuticals Ltd Enterprise Value has shown the following historical trend:
- 2024: 1335Cr
- 2023: 603Cr
- 2022: 651Cr
- 2021: 775Cr
- 2020: 153Cr
The recent rise in Jagsonpal Pharmaceuticals Ltd Enterprise Value suggests strengthening valuation trends and improving market sentiment.
What Jagsonpal Pharmaceuticals Ltd Enterprise Value Indicates for Investors
The Jagsonpal Pharmaceuticals Ltd Enterprise Value plays a crucial role in understanding the company's financial health and valuation.
This ratio is an important metric used in fundamental analysis of Jagsonpal Pharmaceuticals Ltd.
Jagsonpal Pharmaceuticals Ltd Enterprise Value Analysis Summary
The Jagsonpal Pharmaceuticals Ltd Enterprise Value remains a crucial metric for evaluating the company's valuation and financial stability. Investors tracking Jagsonpal Pharmaceuticals Ltd Enterprise Value should also monitor related metrics such as P/E, P/B, EV/EBITDA, D/E, and ROE to get a complete fundamental picture.
Regular tracking of Jagsonpal Pharmaceuticals Ltd Enterprise Value helps investors make informed decisions based on long-term growth, valuation trends, and financial performance.